REFERENCES
- Concorde Coordinating Committee. Concorde: MRC/ ANRS randomised double-blind controlled trial of immedi-ate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871–881.
- Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283–291.
- Hammer S, Katzenstein D, Hughes M, et al., for the AIDS Clinical Trials Group Study 175 Study Team. A trial com-paring nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimiter. N Engl J Med. 1996; 335:1080–1090.
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
- Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS. 1997;11:F101–F105.
- Cameron D, Heath-Chiozzi M, Danner S, et al., for the Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in ad-vanced HIV-1 disease. Lancet. 1998;351:543–549.
- Stellbrink HJ, Hawkins D, Clumeck N, et al. Randomised, multicenter phase III of saquinavir plus zidovudine plus zalcibatine in previously untreated or minimally pretreated HIV-infected patients. Clin Drug Invest. 2000;20:295–307.
- Girard PM, Guiguet M, Bollens D, et al., and the Triest Cohort Investigators. Long-term outcome and treatment modifications in a prospective cohort of human immuno-deficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Clin Infect Dis. 2000;31:987–994.
- Ledergerber B, Egger M, Opravil M, et al., for the Swiss HIV Cohort Study. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet. 1999;353:863–868.
- Le Moing V, Chene G, Carrieri MP, et al., and the APROCO Study Group. Clinical, biological and behavioral predictors of early immunological and virological response in HIV-infected patients initiating protease inhibitors. J Acquired Immun Defic Syndr. Manuscript in revision.
- Mildvan D, Landay A, De Gruttola V, Machado S, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis. 1997;24:764–774.
- O'Brien W, Hartigan P, Daar E, Simberkoff M, Hamilton J, for the VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts pre-dict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 1997;126:939–945.
- Mellors J, Rinaldo C Jr, Gupta P, White R, Todd J, Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
- Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med. 1997;126:929–938.
- Thiébault R, Morlat P, Jacqmin-Gadda H, et al., and the Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA). Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treat-ment. AIDS. 2000;14:971–978.
- Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeosta-sis and function in advanced HIV disease. Science. 1997;277:112–116.
- US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) USPH/IDSA Prevention of Op-portunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMMR. 1999;48(RR10):1–59.